GO:1904595 positive regulation of termination of RNA polymerase II transcription: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904595 describes any process that activates or increases the frequency, rate or extent of termination of RNA polymerase II transcription.
• Termination is coupled to RNA 3'-end processing and is controlled by phosphorylation of the RNA polymerase II C-terminal domain (CTD) and by elongation/termination factors such as SPT5 and P-TEFb.
• SPT5 stabilizes RNA polymerase II, orchestrates transcription cycles and maintains the enhancer landscape, directly influencing termination competence.
• P-TEFb is the master regulator of transcription elongation and also contributes to termination by phosphorylating the CTD and other factors.
• Dysregulation of termination is linked to cancer, viral pathogenesis and developmental disorders, making it a target for therapeutic intervention.
• CRISPR knockout, point mutation, knock-in and overexpression models enable causal dissection of termination-regulatory genes in human cells.
Description
Positive regulation of termination of RNA polymerase II transcription (GO:1904595) is a biological process that increases the frequency, rate or extent of transcription termination by RNA polymerase II. Termination is not a passive event; it is actively promoted by elongation factors, CTD kinases and RNA-processing machinery that together ensure precise 3'-end formation and polymerase release. Understanding this process is essential because termination defects can cause transcriptional read-through, gene dysregulation and genome instability. Researchers study GO:1904595 to define how cells control gene expression boundaries, how enhancer landscapes are maintained and how termination factors contribute to disease. The term is particularly relevant in cancer biology, virology and neurodevelopment, where termination-regulatory proteins such as SPT5 and P-TEFb are frequently perturbed.
positive regulation of termination of RNA polymerase II transcription At A Glance
| GO ID | GO:1904595 |
|---|---|
| GO term | positive regulation of termination of RNA polymerase II transcription |
| Ontology | biological_process |
| Synonym | activation of RNA polymerase II transcription termination; positive regulation of RNA 3'-end formation by RNA polymerase II; up regulation of transcription termination from RNA polymerase II promoter |
| Major function | Increases the frequency, rate or extent of RNA polymerase II transcription termination |
| Related processes | Transcription elongation, RNA 3'-end processing, CTD phosphorylation |
| Key regulators | SPT5, P-TEFb (CDK9/cyclin T), BRD4, TFII-I |
| Cellular context | Nucleus, chromatin, transcription factories |
What Is GO:1904595?
GO:1904595, positive regulation of termination of RNA polymerase II transcription, is defined as any process that activates or increases the frequency, rate or extent of termination of RNA polymerase II transcription. In practice, this includes molecular events that promote polymerase II release from DNA, stimulate RNA 3'-end formation and enhance the activity of termination factors. The term is a child of the broader regulation of transcription termination and is specific to RNA polymerase II, distinguishing it from termination by other RNA polymerases.
Why Is positive regulation of termination of RNA polymerase II transcription Important in Cell Biology?
Positive regulation of termination of RNA polymerase II transcription is critical because it defines the end of transcription units, prevents read-through into neighboring genes and ensures proper RNA 3'-end formation. Defects in this process can lead to aberrant gene expression, genomic instability and disease, including cancer and viral pathogenesis. Studying GO:1904595 helps researchers understand how transcription cycles are coordinated and how termination factors can be targeted therapeutically.
• Ensures precise gene boundaries and prevents transcriptional interference.
• Couples transcription termination to RNA 3'-end processing and polyadenylation.
• Regulates enhancer landscape and transcription cycle dynamics.
• Influences viral gene expression, including HIV Tat-mediated transcription.
• Modulates cancer cell proliferation through BRD4 and P-TEFb.
• Affects neurodevelopment via TFII-I and other termination-related factors.
• Provides targets for therapeutic intervention in cancer and viral infections.
• Enables CRISPR-based functional genomics of termination pathways.
What Happens During positive regulation of termination of RNA polymerase II transcription?
CTD phosphorylation and elongation factor recruitment
In simple terms: Phosphorylation of the polymerase tail recruits factors that help stop transcription.
Positive regulation of termination begins with phosphorylation of the RNA polymerase II C-terminal domain (CTD), particularly at Ser2 and Ser5, by kinases such as P-TEFb (CDK9/cyclin T). This phosphorylation recruits elongation and termination factors, including SPT5, which stabilizes RNA polymerase II and orchestrates transcription cycles. P-TEFb is considered the master regulator of transcription elongation and also contributes to termination by modifying the CTD and other factors.
SPT5-mediated stabilization and enhancer landscape maintenance
In simple terms: SPT5 keeps the polymerase stable and helps maintain active enhancers.
SPT5 (SUPT5H) stabilizes RNA polymerase II, orchestrates transcription cycles and maintains the enhancer landscape. Loss of SPT5 leads to defective termination and read-through transcription, demonstrating its role in positive regulation of termination. SPT5 also interacts with the CTD and other elongation factors to coordinate termination with RNA processing.
RNA 3'-end formation and polyadenylation coupling
In simple terms: The new RNA is cut and given a poly-A tail, which helps end transcription.
Termination is tightly coupled to RNA 3'-end formation, including cleavage and polyadenylation. Positive regulation of termination increases the efficiency of these processing events, ensuring that the polymerase releases from DNA after the polyadenylation signal. This coupling prevents read-through and maintains gene expression boundaries.
BRD4 and JNK-mediated switching of termination functions
In simple terms: BRD4 can change its role after being phosphorylated, affecting how transcription ends.
Phosphorylation by JNK switches BRD4 functions, altering its interaction with P-TEFb and other termination-related complexes. This switch can promote or inhibit termination depending on cellular context, highlighting the dynamic regulation of GO:1904595. BRD4 is a key regulator of transcription elongation and termination, and its modification by JNK provides a mechanism for signal-dependent control.
TFII-I and initiation-elongation-termination coordination
In simple terms: TFII-I helps connect the start and end of transcription.
TFII-I regulates RNA polymerase II transcription initiation and elongation, and also influences termination by modulating factor recruitment. Its role in coordinating different phases of transcription ensures that termination is properly timed. TFII-I is therefore part of the regulatory network that positively regulates termination.
Key Genes Involved in GO:1904595 positive regulation of termination of RNA polymerase II transcription
The following genes and proteins are central to positive regulation of termination of RNA polymerase II transcription, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPT5 (SUPT5H) | Stabilizes RNA polymerase II, orchestrates transcription cycles, maintains enhancer landscape | Knockout causes termination defects and read-through |
| CDK9 | Catalytic subunit of P-TEFb, phosphorylates CTD and termination factors | Target for inhibition in cancer and viral infections |
| CCNT1 (Cyclin T1) | Regulatory subunit of P-TEFb, controls kinase activity | Essential for HIV Tat-mediated transcription |
| BRD4 | Binds acetylated chromatin, recruits P-TEFb, regulated by JNK phosphorylation | Therapeutic target in cancer |
| TFII-I (GTF2I) | Regulates initiation and elongation, influences termination | Implicated in neurodevelopmental disorders |
| CDK12 | Phosphorylates CTD Ser2, regulates termination and DNA repair genes | Potential target in cancer |
| CDK13 | Phosphorylates CTD, regulates transcription and termination | Linked to developmental disorders |
| XRN2 | 5'-3' exonuclease that promotes termination by degrading nascent RNA | Key termination factor |
| SETX | RNA helicase involved in termination and RNA processing | Mutations cause neurodegenerative disease |
| CPSF | Cleavage and polyadenylation specificity factor, couples 3'-end processing to termination | Essential for termination |
| CSTF | Cleavage stimulation factor, required for polyadenylation and termination | Essential for termination |
| PAP (PAPOLA) | Poly(A) polymerase, adds poly-A tail, promotes termination | Required for efficient termination |
| TAT | HIV protein that recruits P-TEFb to viral promoter, enhances termination | Viral pathogenesis |
| ELL2 | Elongation factor that enhances polymerase II processivity and termination | Regulates transcription cycles |
| AFF4 | Component of super elongation complex, regulates P-TEFb | Involved in leukemia |
| MLLT3 | Part of super elongation complex, regulates transcription | Leukemia-associated |
| HEXIM1 | Inhibits P-TEFb by sequestering it in 7SK snRNP | Regulates termination |
| LARP7 | Binds 7SK snRNA, regulates P-TEFb availability | Controls transcription |
How Is positive regulation of termination of RNA polymerase II transcription Regulated?
Positive regulation of termination of RNA polymerase II transcription is itself regulated by signaling pathways that modify termination factors. For example, JNK-mediated phosphorylation of BRD4 switches its function, altering its interaction with P-TEFb and other complexes. P-TEFb activity is controlled by its association with HEXIM1 and 7SK snRNP, which sequesters the kinase and limits termination. Additionally, viral proteins such as HIV Tat recruit P-TEFb to viral promoters, enhancing termination and viral gene expression. These regulatory layers ensure that termination is responsive to cellular signals and environmental cues.
positive regulation of termination of RNA polymerase II transcription and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BRD4 | Cancer, transcription dysregulation | Knockout or point-mutation cell lines |
| CDK9 | Cancer, HIV | Overexpression and knockout models |
| GTF2I | Williams syndrome, neurodevelopmental disorders | Knock-in of patient mutations |
| SETX | Amyotrophic lateral sclerosis, ataxia | Knockout and knock-in models |
| TAT | HIV pathogenesis | Overexpression in T cells |
Cancer
Dysregulation of termination factors such as BRD4 and P-TEFb is common in cancer. BRD4 phosphorylation by JNK switches its functions, affecting transcription of oncogenes and tumor suppressors. P-TEFb is a master regulator of elongation and termination, and its inhibition is a therapeutic strategy in multiple cancers. Targeting positive regulation of termination may therefore provide new anticancer approaches.
Viral pathogenesis
HIV Tat recruits P-TEFb to the viral promoter, enhancing transcription elongation and termination to produce viral RNA. P-TEFb goes viral, as reviewed by Zaborowska et al., highlighting its role in HIV and other viral infections. Understanding GO:1904595 in this context may inform antiviral therapies.
Neurodevelopmental disorders
TFII-I, encoded by GTF2I, regulates transcription initiation, elongation and termination, and is implicated in neurodevelopmental disorders such as Williams syndrome. Mutations affecting termination factors like SETX cause neurodegenerative disease. Thus, positive regulation of termination is critical for neuronal function.
From positive regulation of termination of RNA polymerase II transcription-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SPT5 loss affect termination efficiency? | SPT5 knockout cell line |
| How does BRD4 phosphorylation alter termination? | BRD4 point-mutation knock-in |
| Can P-TEFb inhibition enhance termination? | CDK9 overexpression and knockout |
| What is the role of TFII-I in termination? | GTF2I knockout and knock-in |
| How does HIV Tat recruit P-TEFb? | Tat overexpression in T cells |
| Does XRN2 promote termination? | XRN2 knockout |
How to Study the positive regulation of termination of RNA polymerase II transcription Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression and read-through transcripts | Termination efficiency |
| 3'-end sequencing | RNA 3'-end formation and polyadenylation sites | Termination site mapping |
| ChIP-seq | RNA polymerase II occupancy and CTD phosphorylation | Termination defects |
| Phosphoproteomics | Phosphorylation of termination factors | Signaling regulation |
| CRISPR screen | Genes affecting termination | Functional genomics |
| Co-IP/MS | Protein interactions | Complex composition |
| Nascent RNA labeling | Transcription rate and termination | Dynamic regulation |
RNA-seq and 3'-end sequencing
RNA-seq and specialized 3'-end sequencing methods measure read-through transcription and termination efficiency. These approaches quantify changes in RNA 3'-end formation upon knockout or overexpression of termination factors.
ChIP-seq and chromatin profiling
ChIP-seq for RNA polymerase II and its phosphorylated forms reveals polymerase occupancy and termination defects. It can also assess enhancer landscape changes upon SPT5 perturbation.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics identifies interactions and phosphorylation events on termination factors such as BRD4 and P-TEFb. This helps define signaling pathways that regulate termination.
CRISPR screens and functional genomics
Genome-wide CRISPR screens can identify genes that positively regulate termination. Libraries targeting kinases, RNA-binding proteins and transcription factors enable unbiased discovery.
How CRISPR Can Be Used to Study GO:1904595 positive regulation of termination of RNA polymerase II transcription
Knockout
CRISPR knockout of termination factors such as SPT5, XRN2 or CDK9 can reveal their essential roles in positive regulation of termination. Knockout cell lines show read-through transcription and altered gene expression, providing causal evidence.
Point Mutation
Point mutations in phosphorylation sites of BRD4 or CDK9 can dissect signaling-dependent termination. For example, mutating JNK phosphorylation sites on BRD4 prevents its functional switch.
Knock-in
Knock-in of patient-derived mutations in GTF2I or SETX allows study of termination defects in disease contexts. Tagged knock-in of SPT5 enables localization and interaction studies.
Overexpression
Overexpression of P-TEFb components or HIV Tat enhances termination and can model viral pathogenesis. Overexpression of dominant-negative termination factors can inhibit the process.
How EDITGENE Supports positive regulation of termination of RNA polymerase II transcription Research
Researchers studying positive regulation of termination of RNA polymerase II transcription-related genes often need to determine whether a candidate gene is causally involved in termination efficiency, RNA 3'-end formation or disease-associated read-through. EDITGENE provides CRISPR-based cell models and screening services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of termination of RNA polymerase II transcription research.
Frequently Asked Questions About positive regulation of termination of RNA polymerase II transcription
What is GO:1904595?
GO:1904595 is the Gene Ontology term for positive regulation of termination of RNA polymerase II transcription, describing any process that activates or increases the frequency, rate or extent of transcription termination by RNA polymerase II.
What genes are involved in positive regulation of termination of RNA polymerase II transcription?
Key genes include SPT5, CDK9, CCNT1, BRD4, TFII-I, XRN2, SETX and CPSF, among others.
How does P-TEFb regulate transcription termination?
P-TEFb phosphorylates the RNA polymerase II CTD and other factors, promoting elongation and termination.
What happens when termination is defective?
Defective termination can cause read-through transcription, gene dysregulation and genomic instability, contributing to cancer and other diseases.
Which diseases are linked to termination defects?
Cancer, viral infections such as HIV, and neurodevelopmental disorders like Williams syndrome have been linked to termination dysregulation.
How can I study positive regulation of termination in the lab?
Common methods include RNA-seq, 3'-end sequencing, ChIP-seq, proteomics and CRISPR screens.
What is the role of SPT5 in termination?
SPT5 stabilizes RNA polymerase II, orchestrates transcription cycles and maintains the enhancer landscape, thereby promoting termination.
How does HIV Tat affect termination?
HIV Tat recruits P-TEFb to the viral promoter, enhancing transcription elongation and termination.
Can CRISPR be used to study termination factors?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are widely used to dissect termination mechanisms.
What services does EDITGENE offer for termination research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening and bioinformatics services.
Conclusion
Positive regulation of termination of RNA polymerase II transcription (GO:1904595) is a fundamental process that ensures precise gene boundaries and couples transcription to RNA processing. Its dysregulation is implicated in cancer, viral pathogenesis and neurodevelopmental disorders, making it a rich area for therapeutic targeting. CRISPR-based models and functional genomics provide powerful tools to dissect the mechanisms and disease relevance of this process.
References
- 1. Hu S et al.. 2021. SPT5 stabilizes RNA polymerase II, orchestrates transcription cycles, and maintains the enhancer landscape.. Mol Cell 81(21):4425-4439.e6 PMID: 34534457
- 2. Fujinaga K et al.. 2023. P-TEFb: The master regulator of transcription elongation.. Mol Cell 83(3):393-403 PMID: 36599353
- 3. Linzer N et al.. 2021. Regulation of RNA Polymerase II Transcription Initiation and Elongation by Transcription Factor TFII-I.. Front Mol Biosci 8:681550 PMID: 34055891
- 5. Zaborowska J et al.. 2016. P-TEFb goes viral.. Bioessays 38 Suppl 1:S75-85 PMID: 27417125
- 6. Devaiah BN et al.. 2024. Phosphorylation by JNK switches BRD4 functions.. Mol Cell 84(22):4282-4296.e7 PMID: 39454579
- 7. Zaborowska J et al.. 2016. P-TEFb goes viral.. Inside Cell 1(2):106-116 PMID: 27398404
- 8. Karn J. 1999. Tackling Tat.. J Mol Biol 293(2):235-54 PMID: 10550206
